Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study

Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study

Background: Previous findings on using Glucagon-like peptide-1 receptor agonist (GLP1-RA) as an antidepressant were conflicting, lacking large-scale studies. We used population-based data to investigate depression and anxiety risk in diabetic patients receiving the medication.Methods: From claims re...

Full description

Bibliographic Details
Main Authors:	Wen-Hsuan Tsai, Fung-Chang Sung, Lu-Ting Chiu, Ying-Hsiu Shih, Ming-Chieh Tsai, Shu-I Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Series:	Frontiers in Pharmacology
Subjects:	depression anxiety glucagon-like peptide-1 receptor agonist diabetes neuroendocrine
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.765446/full

Similar Items

Corrigendum: Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study
by: Wen-Hsuan Tsai, et al.
Published: (2022-03-01)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
by: Agnieszka Jakubowska, et al.
Published: (2024-02-01)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
by: Yumie Takeshita, et al.
Published: (2022-06-01)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017-03-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case–control study
by: Wen-Hsuan Tsai, et al.
Published: (2023-10-01)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

Relationship between Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Chronic Respiratory Disease and Diabetes
by: Jun-Jun Yeh, et al.
Published: (2024-02-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy
by: Toshiko Kobori, et al.
Published: (2023-06-01)

Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin
by: Hsuan-Wen Chou, et al.
Published: (2022-12-01)

Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy
by: Chunyan Liu, et al.
Published: (2024-01-01)

Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity
by: Jiska van Schaik, et al.
Published: (2020-08-01)

Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study
by: Joana Freitas, et al.
Published: (2024-04-01)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
by: Yu Mi Kang, et al.
Published: (2016-06-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024-01-01)

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
by: Wang W, et al.
Published: (2023-02-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2018-12-01)

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
by: Bruno Vergès, et al.
Published: (2022-11-01)

Glucagon-like Peptide-1 Receptor Activation Reduces Pulmonary Vein Arrhythmogenesis and Regulates Calcium Homeostasis
by: Chao-Shun Chan, et al.
Published: (2023-08-01)

Obesity, heart failure with preserved ejection fraction, and the role of glucagon‐like peptide‐1 receptor agonists
by: Giuliana Cimino, et al.
Published: (2024-04-01)

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
by: Xinrui Tan, et al.
Published: (2023-03-01)

Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists
by: Qinchao Wu, et al.
Published: (2022-09-01)

Efficacy of once‐daily glucagon‐like peptide‐1 receptor agonist lixisenatide as an add‐on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐level pooled analysis of phase III studies
by: Fuqiang Liu, et al.
Published: (2021-08-01)

A case of multiple glucagonomas with no clinical manifestations of excess glucagon despite hyperglucagonemia
by: Shogo Amano, et al.
Published: (2023-04-01)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
by: Ren Q, et al.
Published: (2022-10-01)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
by: David C. D. Hope, et al.
Published: (2021-09-01)

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement
by: Giorgino F, et al.
Published: (2018-05-01)

A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment
by: Chooi Yeng Lee
Published: (2021-09-01)

Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas
by: Tiina Vesterinen, et al.
Published: (2023-10-01)

Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study
by: Yen-Chieh Lee, et al.
Published: (2022-09-01)

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
by: Caroline Holm Nørgaard, et al.
Published: (2022-01-01)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
by: Giuseppe Lisco, et al.
Published: (2023-10-01)

The Effect of Feeding Behavior on Hypothalamus in Obese Type 2 Diabetic Rats with Glucagon-like Peptide-1 Receptor Agonist Intervention
by: Ke Lu, et al.
Published: (2018-05-01)

First-in-class positron emission tomography tracer for the glucagon receptor
by: Irina Velikyan, et al.
Published: (2019-02-01)

Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
by: Tim Hropot, et al.
Published: (2023-05-01)

Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists
by: Kosuke Sawami, et al.
Published: (2022-09-01)

New uses and formulations of glucagon for hypoglycaemia
by: Pilar I Beato-Víbora, et al.
Published: (2019-07-01)

New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
by: Won-Young Lee
Published: (2017-02-01)